Brief: Novonesis Says Outlook For FY Adjusted EBITDA Margin Is Now 37-38%
19/08/2026 16:40
BRIEF-Novonesis Says Outlook For FY Adjusted EBITDA Margin Is Now 37-38% Aug 19 (Reuters) - Novozymes A/S NSISb.CO:
NOVONESIS OUTLOOK FY ADJUSTED EBITDA MARGIN 37-38%
NOVONESIS - NOVONESIS RAISES FY2026 ORGANIC SALES GROWTH OUTLOOK TO 7-8% FROM 5-7%
Source text: ID:nGNE20K5zT
Further company coverage: [NSISb.CO]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novozymes A/S
See all newsGivaudan jumps on fragrance outperformance; peers follow
Europe Research Roundup: IWG, Londonmetric, Sartorius
Brief: Novonesis To Build Next Generation Enzyme Production Facility In India
Next cycle in ingredient makers sector belongs to biotech, Jefferies says
Europe Research Roundup: DSM-Firmenich, Merck, Orsted